131 results on '"Azevedo, Valderilio F."'
Search Results
2. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials
3. Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis
4. Patient Perception of Medical Care for Psoriatic Arthritis in North America and Europe: Results from a Global Patient Survey
5. Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases
6. Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials
7. Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib
8. Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials
9. Exploring the Quality of Communication Between Patients with Psoriatic Arthritis and Physicians: Results of a Global Online Survey
10. An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data
11. Prevalence, demographics, and clinical characteristics of Latin American patients with spondyloarthritis
12. TNF-α–induced protein 3 (TNFAIP3)/A20 acts as a master switch in TNF-α blockade–driven IL-17A expression
13. Quality of life in spondyloarthritis: analysis of a large Brazilian cohort
14. Biothérapies en rhumatologie en Amérique Latine, en Europe, en Russie et en Inde : produits innovants, biosimilaires et prétendues copies
15. Evaluation of performance of BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) in a Brazilian cohort of 1492 patients with spondyloarthritis: data from the Brazilian Registry of Spondyloarthritides (RBE)
16. Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: Innovators, biosimilars, and intended copies
17. Epidemiologic profile of juvenile-onset compared to adult-onset spondyloarthritis in a large Brazilian cohort
18. Profile of the use of disease modifying drugs in the Brazilian Registry of Spondyloarthritides
19. Enteropathic arthritis in Brazil: data from the Brazilian registry of spondyloarthritis
20. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
21. Etanercept biosimilars
22. Prevention and management of herpes zoster in patients with rheumatoid arthritis and psoriatic arthritis: a clinical review
23. Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials
24. Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib
25. Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials
26. Biosimilars in rheumatology: perspective and concerns
27. Pelvic Finger: An Unusual Cause of Pelvic Pain
28. AB0454 FREQUENCY AND DURATION OF EARLY NON-SERIOUS ADVERSE EVENTS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOFACITINIB 5 MG TWICE DAILY AS MONOTHERAPY AND COMBINATION THERAPY
29. FRI0462 UNDERSTANDING MEDIATORS OF PAIN REDUCTION IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH TOFACITINIB: ROLE OF INFLAMMATION
30. AB0768 BASELINE PAIN SEVERITY AS A PREDICTOR OF PAIN IMPROVEMENT FOLLOWING TREATMENT WITH TOFACITINIB IN PSORIATIC ARTHRITIS
31. AB0449 PAIN REDUCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING TOFACITINIB MONOTHERAPY WITH OR WITHOUT PAIN MEDICATION: A POST HOC ANALYSIS OF POOLED DATA FROM PHASE 2, PHASE 3 AND PHASE 3B/4 STUDIES
32. AB0440 CHANGES IN KEY LABORATORY VALUES WITH TOFACITINIB 5 MG BID TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS AND RHEUMATOID ARTHRITIS
33. Manolo Hugué: from sculpture to painting due to arthritis
34. Manolo Hugué: de la escultura a la pintura a causa de la artritis
35. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study
36. TNF-α–induced protein 3 (TNFAIP3) /A20 acts as a master switch in TNF-α blockade–driven IL-17A expression
37. Proceedings of the GRAPPA 2016 Retreat
38. Erratum of “Enteropathic arthritis in Brazil: data from the Brazilian registry of spondyloarthritis”
39. Epidemiologic profile of juvenile-onset compared to adult-onset spondyloarthritis in a large Brazilian cohort
40. The presence of the Brazilian rheumatology in the GRAPPA
41. Effect of pegylated phosphatidylserine-containing liposomes in experimental chronic arthritis
42. Errata de “Perfil epidemiológico da espondiloartrite de início juvenil comparada com a espondiloartrite de início na vida adulta em uma grande coorte brasileira”
43. Erratum on “Epidemiologic profile of juvenile-onset compared to adult-onset spondyloarthritis in a large Brazilian cohort”
44. Perfil epidemiológico da espondiloartrite de início juvenil comparada com a espondiloartrite de início na vida adulta em uma grande coorte brasileira
45. Etanercept biosimilars
46. The Experience with Biosimilars of Infliximab in Rheumatic Diseases
47. A presença da reumatologia brasileira no GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis)
48. Pelvic Finger
49. Effect of pegylated phosphatidylserinecontaining liposomes in experimental chronic arthritis.
50. An analysis of 372 patients with anterior uveitis in a large Ibero-American cohort of spondyloarthritis: the RESPONDIA Group.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.